Anti-human IFNAR1 recombinant monoclonal antibodies
Anifrolumab biosimilar antibodies comprise the variable region of Anifrolumab and either the same constant region of Anifrolumab or a different one with distinct effector functions (ADCC and ADCP).
Anifrolumab which contains a mutated IgG1(L234F/L235E/P331S) effectorless constant region, displays no effector functions; the other biosimilar features an IgG1 constant region that exhibits high effector functions. These two non-therapeutic antibodies can be used for the comparative study of the complex interactions induced by their Fc domains.
Key features
- Each lot is functionally tested and validated
- Choice of different isotypes for high/low effector functions
- The complete sequence of the antibody constructs has been verified
- Absence of endotoxins determined by the EndotoxDetect assay
Anifrolumab background
Anifrolumab, a fully human monoclonal antibody (mAb), was designed to target the type I interferon (IFN) receptor subunit 1 (IFNAR1) and to block the type I IFN signaling. Anifrolumab features a human IgG1 constant region with a triple mutation L234F/L235E/P331S in the heavy chain. This mutation reduces the engagement with the cell surface Fc gamma receptor (FcγR) and potential Fc-mediated effector function, such as antibody-dependent cell-mediated cytotoxicity (ADCC). According to the FDA, it is a first-in-class medication highlighting its innovative and unique mechanism of action. It has been approved as an add-on therapy for moderately to severely active systemic lupus erythematosus (SLE).
